See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
SynBioVen is an independent investment vehicle launched in 2022 with a £20m commitment from Sir David Harding, focused exclusively on supporting the next generation of synthetic biology scientists, founders, and start-ups in the UK. The firm believes that synthetic biology will drive the next industrial revolution and the transition to a net-zero economy, with UK companies playing a leading role. SynBioVen provides proof-of-concept, pre-seed, and seed funding, and works closely with SynbiCITE and the London Biofoundry to offer portfolio companies access to world-class R&D infrastructure, deep technical expertise in synthetic biology research, business development, and financing. It focuses particularly on companies with a clear mission to use synthetic biology for the public good — including sustainable textiles, agriculture, therapeutics, and industrial biotechnology.
Notable quotes
“Britain is one of the world leaders in Synthetic Biology, one of the most important and exciting new general purpose technologies. It has the capacity to feed us, fuel us and heal us. The challenge is successfully to apply and commercialise the research emerging from our university laboratories. We hope SBV will help make that happen.”
“I am very excited by the launch of SynBioVen which will not only accelerate the UK to become a leading innovator in the Synthetic Biology revolution but also in the development of applications for a sustainable future.”
“We're very excited to partner with the Resurrect Bio team, as their unique technology not only reduces the use of agrichemicals, but it also helps increase crop yields and thereby contributes to addressing the growing food security issues the world is facing.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Resurrect Bio | Series A | $10m | 2026-02-18 |
| HotHouse Therapeutics | Pre-Seed | $2m | 2025-12-02 |
| Scindo | Series A | — | 2025-09-23 |
| Solena Materials | Seed | — | 2025-05-02 |
| Generare | Seed | — | 2024-10-07 |
| Chain Biotech | Seed | — | 2023-07-26 |
| Colorifix | Seed | — | — |
| Eden Bio | Seed | $1m | 2022-11-01 |
| Multus | Seed | — | — |
| Valink Therapeutics | Seed | — | — |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| UK Innovation & Science Seed Fund (UKI2S) | 4 |
| AgFunder | 2 |
| Corteva Agriscience (Corteva Catalyst) | 2 |
| BGF (Business Growth Fund) | 1 |
| Kadmos Capital | 1 |
| Teampact Ventures | 1 |
Fit check
Is SynBioVen a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit